Literature DB >> 32091434

Tumor-insular Complex in Neoadjuvant Treated Pancreatic Ductal Adenocarcinoma Is Associated With Higher Residual Tumor.

Iván A González1, Liang-I Kang1, Gregory A Williams2, Jingxia Liu3, David G DeNardo1,4, William G Hawkins2, Deyali Chatterjee1.   

Abstract

The tumor microenvironment in pancreatic ductal adenocarcinoma (PDAC) plays a vital role in treatment response, and therefore, patient survival. We and others have observed an intimate association of neoplastic ductal cells with non-neoplastic islet cells, recapitulating the ductoinsular complex. We define this phenomenon as tumor-insular complex (TIC). Herein, we describe the clinicopathologic characteristics of TIC in neoadjuvant treated PDAC cases for the first time. We retrospectively reviewed the pathology of 105 cases of neoadjuvant treated PDAC resected at our institution. TIC was noted in 35 cases (33.3%), the mean tumor bed size was 2.7±1.0 cm, mean percentage of residual tumor 40±28% and mean Residual Tumor Index (RTI) (an index previously established as a prognostic parameter by our group) was 1.1±1.0. TIC was significantly associated with perineural invasion (P=0.001), higher tumor bed size (P=0.007), percentage of residual tumor (P=0.009), RTI (P=0.001), ypT stage (P=0.045), and poor treatment response, grouped by a previously established criteria (P=0.010). Using our prior binary reported prognostic cutoff for RTI of ≤0.35 and >0.35, TIC was associated with a RTI >0.35 (P=0.002). Moreover, patients who did not receive neoadjuvant radiation were associated with a higher frequency of TIC (P=0.003). In this cohort, RTI but not TIC was also shown to be a significant independent prognosticator for recurrence-free survival and overall survival on multivariate analysis. In conclusion, TIC is significantly associated with a more aggressive neoplasm which shows a poor treatment response. Further studies will be needed to better understand the tumor biology of TICs.

Entities:  

Mesh:

Year:  2020        PMID: 32091434      PMCID: PMC7225071          DOI: 10.1097/PAS.0000000000001454

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.298


  42 in total

Review 1.  The islet-acinar axis of the pancreas: more than just insulin.

Authors:  Savio G Barreto; Colin J Carati; James Toouli; Gino T P Saccone
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-04-15       Impact factor: 4.052

2.  Validation of a Proposed Tumor Regression Grading Scheme for Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy as a Prognostic Indicator for Survival.

Authors:  Sun Mi Lee; Matthew H G Katz; Li Liu; Manonmani Sundar; Hua Wang; Gauri R Varadhachary; Robert A Wolff; Jeffrey E Lee; Anirban Maitra; Jason B Fleming; Asif Rashid; Huamin Wang
Journal:  Am J Surg Pathol       Date:  2016-12       Impact factor: 6.394

Review 3.  New insights into pancreatic cancer-induced paraneoplastic diabetes.

Authors:  Raghuwansh P Sah; Sajan Jiv Singh Nagpal; Debabrata Mukhopadhyay; Suresh T Chari
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-03-26       Impact factor: 46.802

4.  Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer.

Authors:  Francis I Macedo; Emily Ryon; Shishir K Maithel; Rachel M Lee; David A Kooby; Ryan C Fields; William G Hawkins; Greg Williams; Ugwuji Maduekwe; Hong J Kim; Syed A Ahmad; Sameer H Patel; Daniel E Abbott; Patrick Schwartz; Sharon M Weber; Charles R Scoggins; Robert C G Martin; Vikas Dudeja; Dido Franceschi; Alan S Livingstone; Nipun B Merchant
Journal:  Ann Surg       Date:  2019-09       Impact factor: 12.969

5.  Pancreatic cancer cells selectively stimulate islet beta cells to secrete amylin.

Authors:  X Ding; P R Flatt; J Permert; T E Adrian
Journal:  Gastroenterology       Date:  1998-01       Impact factor: 22.682

Review 6.  Pancreatic ductal adenocarcinoma: risk factors, screening, and early detection.

Authors:  Andrew E Becker; Yasmin G Hernandez; Harold Frucht; Aimee L Lucas
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

Review 7.  Advances in pancreatic cancer research: moving towards early detection.

Authors:  Xiang-Yi He; Yao-Zong Yuan
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

8.  VNN1, a potential biomarker for pancreatic cancer-associated new-onset diabetes, aggravates paraneoplastic islet dysfunction by increasing oxidative stress.

Authors:  Muxing Kang; Wenjie Qin; Miranbieke Buya; Xin Dong; Wen Zheng; Wenjie Lu; Jian Chen; Qingqu Guo; Yulian Wu
Journal:  Cancer Lett       Date:  2016-02-01       Impact factor: 8.679

9.  Tumor-driven like macrophages induced by conditioned media from pancreatic ductal adenocarcinoma promote tumor metastasis via secreting IL-8.

Authors:  Shao-Jie Chen; Guo-da Lian; Jia-Jia Li; Qiu-Bo Zhang; Lin-Juan Zeng; Ke-Ge Yang; Chu-Mei Huang; Ya-Qing Li; Yin-Ting Chen; Kai-Hong Huang
Journal:  Cancer Med       Date:  2018-10-12       Impact factor: 4.452

10.  Stromal mesenchymal stem cells facilitate pancreatic cancer progression by regulating specific secretory molecules through mutual cellular interaction.

Authors:  Ken Saito; Masakiyo Sakaguchi; Satoshi Maruyama; Hidekazu Iioka; Endy Widya Putranto; I Wayan Sumardika; Nahoko Tomonobu; Takashi Kawasaki; Keiichi Homma; Eisaku Kondo
Journal:  J Cancer       Date:  2018-07-30       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.